RenaSci provides an integrated blend of in vivo pharmacology consultancy and experimental services. We help clients, from all sectors of the pharmaceutical and biotech industry, to maximise their research productivity and streamline drug development.
The company was founded in 2001 by Dr Sharon Cheetham, Dr Rob Jones and Professor David Heal, who were senior members of the R&D team at BASF Pharma. RenaSci specialises in these key therapeutic areas:
RenaSci Facts at a Glance
Our clients include pharma, biotech, virtual companies and healthcare investors from around the world. We collaborate on all stages of the drug development process, from target identification to post-registration market positioning studies.
Renasci’s regulatory expertise, combined with our skills in drug development and abuse liability assessment, have been pivotal to the success of clients in achieving European and US drug registrations.
Our aim is to provide high-quality experimental services, tailored to each sponsor’s specific requirements, and delivered to agreed timelines. We understand that studies may change when they are in progress, and we are both flexible and responsive when it occurs. Data reporting varies from tabulated screening results to fully audited written reports that meet regulatory standards.
Working arrangements with our sponsors range from one off fee-for-service studies through to long term FTE arrangements to ensure the continuity of project work. The fact that almost all of our clients are returning customers is testament to the high quality of our service.
In 2018, RenaSci became part of Sygnature Group, complementing the services of Sygnature Discovery, the leading provider of integrated drug discovery resource and expertise.
For more details or information on how we can support your project please complete the contact form.